Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA RECALLS & COURT ACTIONS: June 9, 1993

Executive Summary

CLASS II - DOXEPIN HYDROCHLORIDE CAPSULES, USP (a) 100 mg, in bottles of 100; (b) 150 mg, in bottles of 50, a Rx anti-depressant. Recall number: D-272/273-3. Control numbers: 346-154 EXP 11/94; 346-155 EXP 12/94. Manufacturer: Lederle Arzneimittel Cyanamid GmbH, Germany. Recalled by: Lederle Laboratories, Division of American Cyanamid Company, Pearl River, New York, by letter May 21, 1993. Firm-initiated recall ongoing. Distribution: Alabama, Arkansas, Colorado, Connecticut, Florida, Louisiana, Maine, Pennsylvania, Kentucky, New Jersey, Virginia, West Virginia, South Carolina, Tennessee, Texas; (a) 1,201 bottles; (b) 1,553 bottles were distributed. Reason: Products do not meet dissolution specifications. CLASS III CHLOROMYCETIN CREAM, 1% (CHLORAMPHENICOL CREAM, USP) In 1 ounce tubes, Rx topical used for the treatment of surface skin infections. Recall number: D-271-3. Lot number 00172B EXP 7/93. Manufacturer: Parke-Davis Canada, Inc., Ontario, Canada. Recalled by: Warner-Lambert Company, Parke-Davis Division, Morris Plains, New Jersey, by letter dated April 26, 1993. Firm-initiated recall ongoing. Distribution: Nationwide; 6,216 tubes were distributed; firm estimates 2,000 tubes remain on the market. Reason: Product does not meet specifications for the propylparaben ingredient.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel